Cytostatic agent derived from methylhydralazine. Mainly used in the treatment of lymphoma and brain tumors.
Severe allergic reactions: 2%, severe toxic effects: 2%, life-threatening allergic reactions: 1% in Hodgkin’s disease.
Much higher (25%) in patients with brain tumors.
Brain tumors, especially when anticonvulsant therapy is used.
Respiratory: cough, dyspnea, acute pulmonary infiltrates, pleural effusion.
Cutaneous: pruritus, urticaria, maculopapular rash (+++), angioedema, fixed drugeruption, toxic epidermal necrolysis.
No in vivo or in vitro method is currently available for diagnosis other than re-challenge (which is hazardous: life-threatening pneumonitis published).
Classical complement pathway activation is possible.
Procarbazine oxidation to a reactive intermediate is enhanced by phenobarbital.
Use non enzyme-inducing anticonvulsants.
Corticosteroids are useful in the management of respiratory manifestations.